UPDATE: Testosterone Therapy Rx Linked to Potentially Fatal Conditions
Follow up to February 2014 Harman Law Post: FDA Requires Label Change Citing Increased Blood Clot Risk with Testosterone Products On June 19, 2014 the FDA announced they are requiring manufacturers of testosterone therapy products (“TT”) to add blood clot warnings to the drug labeling. The testosterone products include: Axiron AndroDerm AndroGel (the biggest seller… Continue reading